Gentris Corporation Expands into International Market with Japan Partnership

Strategic Insights -

Gentris Corporation, a leading service provider of pharmacogenomic testing, has signed a preferred vendor and master services agreement with Quintiles Transnational Japan K.K. (Quintiles Japan), a leading service provider to the pharmaceutical industry in Japan. This partnership marks Gentris' first international expansion, capitalizing on Japan's position as the world's second-largest pharmaceutical market. The collaboration aims to provide unique pharmacogenomics services to Quintiles Japan's customers, leveraging Gentris' proprietary procedures and know-how.

Key Takeaways:

  • Gentris and Quintiles Japan are working on pharmacogenomic projects with several Japanese pharmaceutical companies and are in discussions with others.
  • The partnership allows Quintiles Japan to provide its customers with comprehensive pharmacogenomic services, including DNA isolation and purification, DNA banking, clinical genotyping, and regulatory consulting services.
  • Gentris' services will adhere to international standards of Good Laboratory Practice (GLP) for sample collection, transport, and storage.
  • This agreement is significant, as Japan is the world's second-largest pharmaceutical market, and pharmacogenomics has the potential to improve diagnostics for existing drugs.
  • Pharmacogenomic profiling has the potential to increase the efficiency and speed of new medicine development.
  • The partnership with Quintiles Japan is Gentris' first international expansion, and it positions Gentris as a leader in the pharmacogenomics market.

Statistics:

  • Japan is the world's second-largest pharmaceutical market.
  • Pharmacogenomics is an emerging field, considered one of the first tangible results of the Human Genome Project.
  • The pharmacogenomic testing market is projected to grow from $1.5 billion in 2000 to $3-$4 billion by 2005.
  • Adverse drug reactions are the fourth leading cause of death and the fifth leading cause of illness in the United States.
  • The Gentris Corporation aims to facilitate the development of drugs by predicting their efficacy and decreasing adverse reactions.

Sources:

  • Gentris Corporation
  • Quintiles Transnational Japan K.K.
  • Pharmacogenomics is the study of an individual's genetic profile to predict response to specific drugs.